4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume - Here's Why

Key Points

• 4D Molecular Therapeutics experienced an 86% surge in trading volume to 1,383,618 shares mid‑day, with the stock trading around $10.36 versus a $9.88 close.
• Wall Street is largely optimistic—seven Buys, one Hold and one Sell—resulting in an average rating of Moderate Buy and an average price target of $32.71, with several firms targeting $33–$36.
• The company posted an unexpected quarterly EPS of $0.43 (versus a ‑$0.53 estimate) and revenue of $85.09M (versus $30.86M est.), yet it remains unprofitable with negative margins and a projected FY EPS of ‑2.84.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw an uptick in trading volume on Thursday . 1,383,618 shares traded hands during mid-day trading, an increase of 86% from the previous session's volume of 743,276 shares.The stock last traded at $10.3560 and had previously closed at $9.88.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on FDMT. Wall Street Zen upgraded 4D Molecular Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Barclays assumed coverage on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an "overweight" rating and a $33.00 price objective for the company. Royal Bank Of Canada upped their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an "outperform" rating in a research report on Thursday, March 19th. Chardan Capital reissued a "buy" rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of "Moderate Buy" and an average price target of $32.71.

4D Molecular Therapeutics Price Performance

The stock has a 50 day moving average price of $8.84 and a 200-day moving average price of $9.18. The stock has a market capitalization of $514.07 million, a P/E ratio of -4.14 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%.The firm had revenue of $85.09 million during the quarter, compared to the consensus estimate of $30.86 million. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. RA Capital Management L.P. raised its holdings in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company's stock worth $42,399,000 after purchasing an additional 1,090,000 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of 4D Molecular Therapeutics by 164.4% during the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company's stock worth $34,726,000 after acquiring an additional 2,882,508 shares during the period. BVF Inc. IL raised its position in shares of 4D Molecular Therapeutics by 1.5% in the 2nd quarter. BVF Inc. IL now owns 4,629,289 shares of the company's stock worth $17,175,000 after acquiring an additional 68,000 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in 4D Molecular Therapeutics by 4.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company's stock worth $32,272,000 after purchasing an additional 174,489 shares in the last quarter. Finally, State Street Corp increased its stake in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company's stock worth $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.